Danoprevir, a small-molecule NS3/4A protease inhibitor for the potential oral treatment of HCV infection

Current Opinion in Investigational Drugs

Volumn 11, Issue 8, 2010, Pages 951-963

  Deutsch, Melanie ^a   Papatheodoridis, George V ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

4' AZIDOCYTIDINE; 6 [(TERT BUTOXYCARBONYL) AMINO] 14A [N (CYCLOPROPANESULFONYL) CARBAMOYL] 5,16 DIOXO 1,2,3,4,5,6,7,8,9,10,11,13A,14,14A,15,16,16 ADEXADECAHYDROCYCLOPROPA[E]PYRROLO[1,2 A][1,4] DIAZACYCLOPENTADECIN 2 YL 4 FLUORO 1,3 DIHYDRO 2H ISOINDOLE 2 CARBOXYLATE; ALANINE AMINOTRANSFERASE; ALLOPURINOL; ANTIVIRUS AGENT; AR 003341941; BALAPIRAVIR; BOCEPREVIR; CILUPREVIR; DANOPREVIR; ITMN 191; ITMN 8020; ITMN B; PEGINTERFERON ALPHA2A; RG 7128; RIBAVIRIN; RITONAVIR; TELAPREVIR; UNCLASSIFIED DRUG; VIRUS RNA;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; BILIRUBIN BLOOD LEVEL; BLOOD LEVEL; CLINICAL ASSESSMENT; CLINICAL FEATURE; CLINICAL STUDY; CLINICAL TRIAL; DIARRHEA; DISSOCIATION; DRUG BINDING; DRUG BLOOD LEVEL; DRUG ERUPTION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENCY; DRUG POTENTIATION; DRUG SAFETY; DRUG STRUCTURE; DRUG SYNTHESIS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER; LOW DRUG DOSE; NAUSEA; NEUTROPENIA; NONHUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; REVIEW; SAFETY; SIDE EFFECT; SINGLE DRUG DOSE; STRUCTURE ACTIVITY RELATION; TREATMENT PLANNING; TREATMENT RESPONSE; VIRUS RESISTANCE;

ANIMALS; ANTIVIRAL AGENTS; CLINICAL TRIALS AS TOPIC; DOGS; DRUG EVALUATION, PRECLINICAL; DRUG THERAPY, COMBINATION; HAPLORHINI; HEPACIVIRUS; HEPATITIS C; HUMANS; INTERFERON ALFA-2A; LACTAMS; POLYETHYLENE GLYCOLS; PROTEASE INHIBITORS; RATS; RATS, SPRAGUE-DAWLEY; RIBAVIRIN; RITONAVIR; SULFONAMIDES; VIRAL NONSTRUCTURAL PROTEINS;

EID: 77954974327     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (83)

1. 465487 InterMune and Array BioPharma announce drug discovery collaboration focused on hepatitis. InterMune Inc, Array BioPharma Inc Press Release 2002 September 30
2. 574978 Array BioPharma grants InterMune expanded rights under hepatitis C discovery agreement. Array BioPharma Inc Press Release 2004 December 07
3. 613080 InterMune and Array BioPharma expand hepatitis C drug discovery collaboration. InterMune Inc, Array BioPharma Inc Press Release 2005 July 19
4. 667327 Generation and characterization of HCV replicons with reduced sensitivity to ITMN 191, a macrocyclic inhibitor of NS3/4A. Seiwert S, Andrews SW, Tan H, Condroski KR, Ballard JA, Bernat BA, Josey JA, Blatt LM GASTROENTEROLOGY 2006 130 4 Suppl 2 Abs 195
5. 668631 Preclinical characteristics of ITMN 191, an orally active inhibitor of the HCV NS3/4A protease nominated for preclinical development. Seiwert S, Andrews SW, Yang H, Tan H, Marafino B, Rieger R, Franklin RB, Pheneger J, Lee PA, Jiang Y, Kennedy AL et al GASTROENTEROLOGY 2006 130 4 Suppl 2 Abs T1793
6. 668632 Structure-based design of novel isoindolene inhibitors of HCV NS3/4A protease and binding mode analysis of ITMN 191 by X-ray crystallography Condroski K.R. Zhang H. Seiwert S. Ballard J.A. Bernat B.A. Brandhuber B. Colwell H. Smith D. Vigers G. Andrews S.W. Kennedy A.L. et al. GASTROENTEROLOGY 2006 130 4 SUPPL 2 Abs T1794
7. 668633 Pharmacokinetic analysis and liver concentrations of a series of macrocyclic peptidomimetic inhibitors of HCV NS3/4A Protease: Identification of ITMN 191, a potent NS3/4A protease inhibitor with high liver exposure across multiple species. Rieger R, Lee PA, Seiwert S, Andrews SW, Hingorani GP, Pope TK, Pheneger J, Neitzel N, Franklin RB, Josey JA, Blatt LM GASTROENTEROLOGY 2006 130 4 Suppl 2 Abs T1795
8. 676554 Vertex Pharmaceuticals and Janssen Pharmaceutica, a Johnson & Johnson company, form collaboration to develop and commercialize VX-950 for treatment of hepatitis C. Vertex Pharmaceuticals Inc PRESS RELEASE 2006 June 30
9. 731663 Roche and InterMune sign agreement to collaborate on the research, development and commercialization of hepatitis C protease inhibitors. InterMune Inc Press Release 2006 October 16
10. 738076 InterMune closes collaboration agreement with Roche. InterMune Inc Press Release 2006 November 02
11. 756250 InterMune achieves manufacturing milestone in HCV collaboration with Roche. InterMune Inc Press Release 2007 January 09
12. 795496 Characterization of HCV NS3/4A protease inhibition by ITMN-191 reveals picomolar potency and slow dissociation: Implications for the use of ITMN-191 in chronic HCV treatment. Rajagopalan P, Misialek S, Blatt LM, Seiwert SD, Kossen K GASTROENTEROLOGY 2007 132 4 Abs M1816
13. 797539 Digestive Disease Week 2007 (part II) - Overnight report, Washington DC, USA. Chan D IDDB MEETING REPORT 2007 May 19-24
14. 815431 InterMune submits CTA amendment for ITMN-191 and provides update on clinical development program. InterMune Inc Press Release 2007 July 24
15. 827313 InterMune announces approval of clinical trial authorization for phase 1b trial of ITMN-191. InterMune Inc PRESS RELEASE 2007 September 04
16. 891678 InterMune announces top-line results of phase 1b trial of ITMN-191 (R7227) and provides program update. InterMune Inc PRESS RELEASE 2008 April 01
17. 926259 How hepatitis c virus NS3-4A protease R155K/T strains can discriminate VX-950 and ITMN-191 but affect differentially SCH-503034 Courcambeck J. Bouzidi M. Roche G. Pepe G. Halfon P. ANTIVIR THER 2008 13 SUPPL 3 Abs 38
18. 939682 InterMune earns development milestone in HCV protease inhibitor collaboration with Roche. InterMune Inc Press Release 2008 September 02
19. 951690 Unravelling hepatitis C virus replication from genome to function. Lindenbach BD, Rice CM NATURE 2005 436 7053 933-938
20. 951709 Ultra-rapid cardiotoxicity of the hepatitis C virus protease inhibitor BILN 2061 in the urokinase-type plasminogen activator mouse. Vanwolleghem T, Meuleman P, Libbrecht L, Roskams T, De Vos R, Leroux-Roels G GASTROENTEROLOGY 133 4 1144-1155
21. 952755 Relative replication capacity and selective advantage profiles of protease inhibitor-resistant hepatitis C virus (HCV) NS3 protease mutants in the HCV genotype 1b replicon system. He Y, King MS, Kempf DJ, Lu L, Lim HB, Krishnan P, Kati W, Middleton T, Molla A ANTIMICROB AGENTS CHEMOTHER 2008 52 3 1101-1110
22. 975761 InterMune reports results from triple combination study of ITMN-191. InterMune Inc PRESS RELEASE 2009 January 12
23. 977526 Treatment of chronic hepatitis C virus (HCV) genotype 1 patients with the NS3/4A protease inhibitor ITMN-191 leads to rapid reductions in plasma HCV RNA: Results of a phase 1B multiple ascending dose (MAD) study. Forestier N, Larrey DG, Guyader D, Marcellin P, Rouzier R, Patat AA, Bradford WZ, Porter S, Zeuzem S HEPATOLOGY 2008 48 S1 Abs 1847
24. 977539 A phase 1 study of the safety, tolerability, and pharmacokinetics (PK) of single ascending oral doses of the NS3/4A protease inhibitor itmn 191 in healthy subjects. Bradford WZ, Rubino C, Porter S, Forrest A, Blatt LM, Patat AA HEPATOLOGY 2008 48 S1 Abs 1871
25. 977567 Pharmacokinetic-pharmacodynamic (PK-PD) relationships for ITMN-191 in a phase 1 multiple ascending dose trial in patients with genotype 1 chronic hepatitis C (CHC) infection. Rubino C, Bradford WZ, Forrest A, Porter S, Blatt LM, Seiwert S, Zeuzem S HEPATOLOGY 2008 48 S1 Abs 1861
26. 994979 Inhibition and binding kinetics of the hepatitis C virus NS3 protease inhibitor ITMN-191 reveals tight binding and slow dissociative behavior. Rajagopalan R, Misialck S, Stevens SK, Myszka DG, Brandhuber BJ, Ballard JA, Andrews SW, Seiwert SD, Kossen K BIOCHEMISTRY 2009 48 11 2559-2568
27. 1001888 INFORM-1 clinical trial amended to further explore promising direct antiviral regimen in HCV patients. InterMune Inc PRESS RELEASE 2009 April 21
28. 1003132, Ground-breaking combination of all-oral agents demonstrates potential as hepatitis C treatment regimen. Roche Holding AG, InterMune Inc, Pharmasset Ltd PRESS RELEASE, 2009 April, 25
29. 1004474 The hepatitis C virus life cycle as a target for new antiviral therapies. Pawlotsky JM, Chevaliez S, McHutchison JG GASTROENTEROLOGY 2007 132 5 1979-1998
30. 1004828 Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. McHutchison JG, Everson GT, Gordon SC, Jacobson IM, Sulkowski M, Kauffman R, McNair L, Alam J, Muir AJ N ENGL J MED 2009 360 1827-1838
31. 1004842 Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. Hezode C, Forestier N, Dusheiko G, Ferenci P, Pol S, Goeser T, Bronowicki JP, Bourliere M, Gharakhanian S, Bengtsson L, McNair L et al N ENGL J MED 2009 360 18 1839-1850
32. 1014752 Diagnosis, management, and treatment of hepatitis C: An update. Ghany MG, Strader DB, Thomas DL, Seeff LB HEPATOLOGY 2009 49 4 1335-1374
33. 1018631 HCV SPRINT-1 final results: SVR 24 from a phase 2 study of boceprevir plus PegIntron (TM) (peginterferon α-2b)/ribavirin in treatment-nave subjects with genotype-1 chronic hepatitis C. Kwo P, Lawitz E, McCone J, Schiff E, Vierling J, Pound D, Davis M, Galati J, Gordon S, Ravendhran N, Rossaro L et al J HEPATOL 2009 50 Suppl 1 Abs 4
34. 1020300 Suppression of in vitro resistance development after treatment of the HCV replicon with NS3/4A inhibitor ITMN- 191 (R7227) in combination with nucleoside inhibitor R7128 or R1626. McCown M, Rajyaguru S, Kular S, Cammack N, Najera I J HEPATOL 2009 50 Suppl 1 Abs 960
35. 1020319 Incidence of virologic escape observed during ITMN-191 (R7227) monotherapy is genotype dependent, associated with a specific NS3 substitution, and suppressed upon combination with PEGinterferon α-2A/ribavirin. Sarrazin C, Hong J, Lim S, Qin X, Susser S, Bradford B, Porter S, Zeuzem S, Seiwert S J HEPATOL 2009 50 Suppl 1 Abs 964
36. 1020472 Antiviral activity and safety of ITMN-191 in combination with peginterferon α-2A and ribavirin in patients with chronic hepatitis C virus (HCV). Forestier N, Larrey D, Marcellin P, Benhamou Y, Guyader D, Bradford W, Porter S, Patat A, Rouzier R, Zeuzem S J HEPATOL 2009 50 Suppl 1 Abs 85
37. 1020482 Combination of the NS3/4A protease inhibitor ITMN-191 with the allosteric NS5B polymerase inhibitor ITMN-8020 enhances replicon clearance and reduces the emergence of drug resistant variants. Tan H, Wang G, Moy C, Kossen K, Rajagopalan R, Misialek S, Ruhrmund D, Hooi L, Snarskaya N, Stoycheva A, Buckman B et al J HEPATOL 2009 50 Suppl 1 Abs 936
38. 1029685 Vertex Pharmaceuticals and Mitsubishi Tanabe Pharma Corporation amend agreement to develop and commercialize telaprevir in Asia. Vertex Pharmaceuticals Inc PRESS RELEASE 2009 July 30
39. 1032107 InterMune reports second quarter 2009 financial results and business highlights. InterMune Inc PRESS RELEASE 2009 August 06
40. 1035136 Roche and InterMune initiate phase 2b clinical trial of RG7227/ ITMN-191 in patients with chronic hepatitis C. InterMune Inc, Roche Holding AG PRESS RELEASE 2009 August 19
41. 1054106 INFORM-1 results: Robust antiviral suppression achieved with combination of nucleoside analog polymerase inhibitor RG7128 and protease inhibitor RG7227. Pharmasset Inc, InterMune Inc PRESS RELEASE 2009 November 03
42. 1054580 Merck and Schering-Plough to complete merger today. Merck & Co Inc PRESS RELEASE 2009 November 03
43. 1057637 InterMune announces modification to on-going phase 2b study of ITMN-191 in patients with chronic HCV infection. InterMune Inc PRESS RELEASE 2009 November 17
44. 1064404 Pharmacokinetics/pharmacodynamics (PK/PD) of combination R7227 and R7128 therapy from INFORM-1 demonstrates similar early HCV viral dynamics when R7227 is combined with either PEG-IFN/ribavirin (SOC) or R7128. Morcos PN, Kulkarni R, Ipe D, Jumbe S, Tran J, Bradford WZ, Symonds W, Bradford WZ, Gane EJ, Roberts SK, Shulman N et al HEPATOLOGY 2009 50 S4 Abs 1594
45. 1064410 Combination therapy with a nucleoside polymerase (R7128) and protease (R7227/ITMN-191) inhibitor in HCV: Safety, pharmacokinetics, and virologic results from INFORM-1. Gane EJ, Roberts SK, Stedman CA, Angus PW, Ritchie B, Elston R, Ipe D, Morcos PN, Najera I, Chu T, Berrey MM et al HEPATOLOGY 2009 50 S4 Abs 193
46. 1064417 Kinetic analysis of viral rebound and drug-resistant viral variant dynamics in patients treated with ITMN-191 (R7227) monotherapy suggest a high barrier to viral escape. Sarrazin C, Lim S, Qin XL, Susser S, Lange CM, Bradford WZ, Zeuzem S, Kossen K, Najera I, Seiwert S HEPATOLOGY 2009 50 S4 Abs 1411
47. 1064423 Combination therapy with nucleoside polymerase R7128 and protease R7227/ITMN-191 inhibitors in genotype 1 HCV infected patients: Interim resistance analysis of INFORM-1 cohorts A-D. Le Pogam S, Chhabra M, Ali S, Yan JM, Ilnicka MJ, Kang H, Wong JM, Kosaka A, Ewing A, Seshaadri A, De La Rosa A et al HEPATOLOGY 2009 50 4 Suppl 1037A
48. 1065265 HEP DART 2009: Frontiers in drug development for viral hepatitis. Feitelson MA IDDB MEETING REPORT 2009 December 6-10
49. 1075848 InterMune reports fourth quarter and full year 2009 financial results and business highlights. InterMune Inc PRESS RELEASE 2010 February 17
50. 1076186 ITMN A and B, novel inhibitors of the HCVNS3/4 protease retain their potency against VX-950 and BILN-2016 resistant NS3/4 protease mutants and an IFN-a-2a resistant HCV replicon. Seiwert S, Andrews SW, Yang HL, Tan H, Marifino B, Radhakishnan R, Cheung E, Rieger R, Jiang YT, Kennedy A, Wenglowsky S et al HEPATOLOGY 2005 42 Suppl 1 Abs 869
51. 1076187 Preclinical characteristics of ITMN-B, an orally active inhibitor of the HCV NS3/4A protease nominated for preclinical development. Seiwert SD, Andrews SW, Tan H, Wang T, Marafino B, Rieger R, Pheneger J, Lee PA, Jiang Y, Kennedy AL, Ballard J et al J HEPATOL 2006 44 Suppl 2 Abs 750
52. 1076188 In vitro synergistic antiviral activity of ITMN-191, an orally active inhibitor of the hepatitis c virus (HCV) NS3/4A protease, in combination with PEG-interferon α-2a. Tan H, Seiwert SD, Blatt LM HEPATOLOGY 2006 44 S1 Abs 933
53. 1076189 Sequence variation of NS3/4A in HCV replicons exposed to ITMN-191 concentrations encompassing those likely to be achieved following clinical dosing. Seiwert SD, Hong J, Lim SR, Wang T, Tan H, Blatt LM J HEPATOL 2007 46 Suppl 1 Abs 647
54. 1076190 ITMN-191 concentrations achieved in the liver of animals promote HCV replicon clearance in vitro and this effect is enhanced by PEG-IFN α-2a. Blatt LM, Tan H, Seiwert SD J HEPATOL 2007 46 Suppl 1 Abs 576
55. 1076191 Genotype coverage of the HCV NS3/4a protease inhibitor ITMN-191 (R7227): Biochemical data reveals potent inhibition and slow dissociation with genotype 1-6 proteases. Rajagopalan PTR, Stevens S, Stoycheva A, Brandhuber B, Zhang H, Gale M, Blatt LM, Seiwert S, Kossen K HEPATOLOGY 2007 46 S1 Abs 1386
56. 1076193 Additive to synergistic antiviral effects of an NS3/4A protease inhibitor (ITMN-191) and an NS5B RNA-dependent RNA polymerase inhibitor (R1479) in an HCV replicon system. Seiwert SD, Tan H, Blatt LM J HEPATOL 2007 46 Suppl 1 Abs 439
57. 1076195 Preclinical characteristics of the hepatitis C virus NS3/4A protease inhibitor ITMN-191 (R7227). Seiwert SD, Andrews SW, Jiang Y, Serebryany V, Tan H, Kossen K, Rajagopalan PTR, Misialek S, Stevens SK, Stoycheva A, Hong J et al ANTIMICROB AGENTS CHEMOTHER 2008 52 12 4432-4441
58. 1076197 Combination of the NS3/4A protease inhibitor ITMN-191 (R7227) with the active moiety of the NS5B inhibitors R1626 or R7128 enhances replicon clearance and reduces the emergence of drug resistant variants. Tan H, Rajyaguru S, Wu T, McCown M, Ali S, Jiang WR, Otto MJ, Furman PA, Najera I, Klumpp K, Symons J et al HEPATOLOGY 2008 48 S1 Abs 1885
59. 1076201 First-in-man demonstration of potent antiviral activity with a nucleoside polymerase (R7128) and protease (R7227/ITMN191) inhibitor combination in HCV: Safety, pharmacokinetics, and virologic results from INFORM-1. Gane EJ, Roberts SK, Stedman C, Angus PW, Ritchie B, Elston R, Ipe D, Baher L, Morcos P, Najera I, Mannino M et al J HEPATOL 2009 50 Suppl 1 Abs 1046
60. 1085151 Kepler Swiss seminar. Roche Holding AG COMPANY PRESENTATION 2010 March 24 1088499 Telaprevir for previously treated chronic HCV infection. McHutchison JG, Manns MP, Muir AJ, Terrault NA, Jacobson IM, Afdhal NH, Heathcote EJ, Zeuzem S, Reesink HW, Garg J, Bsharat M et al N ENGL J MED 2010 362 14 1292-1303
61. 1090503 InterMune reports top-line results from phase 2b study of danoprevir (RG7227/ITMN-191) in patients with chronic hepatitis C. InterMune Inc PRESS RELEASE 2010 April 14
62. 1091035 InterMune reports virologic response of ritonavirboosted danoprevir (RG7227/ITMN-191) in patients with chronic hepatitis C. InterMune Inc PRESS RELEASE 2010 April 15
63. 1094997 InterMune reports first quarter 2010 financial results and business highlights. InterMune Inc PRESS RELEASE 2010 April 29
64. 1098473 Merck highlights robust late-stage pipeline, global. Merck & Co Inc PRESS RELEASE 2010 May 11
65. 1100818 ITMN-191/R7227 monotherapy in chronic HCV patients reduces plasma concentrations of IP-10 and neopterin. Schaefer CJ, Kossen K, Lim SR, Qin X, Lin J, Pan L, Bradford WZ, Seiwert SD J HEPATOL 2010 52 Suppl 1 Abs 1073
66. 1101179 Impact of low dose ritonavir boosting on the pharmacokinetics of RG7227 (ITMN-191), a highly potent and selective inhibitor of the HCV NS3/4A protease. Haznedar JO, Fretland J, Leong G, Blotner S, Hill T, Smith P, Tran JQ J HEPATOL 2010 52 Suppl 1 Abs 753
67. 1101192 Ritonavir boosting of low dose RG7227/ITMN-191, HCV NS3/4A protease inhibitor, results in robust reduction in HCV RNA at lower exposures than provided by unboosted regimens. Gane E, Rouzier R, Stedman C, Wiercinska-Drapalo A, Horban A, Chang L, Zhang Y, Sampeur P, Najera I, Shulman N, Smith P et al J HEPATOL 2010 52 Suppl 1 Abs 38
68. 1101193 Early on-treatment responses during pegylated IFN plus ribavirin are increased following 13 days of combination nucleoside polymerase (RG7128) and protease (RG7227) inhibitor therapy (INFORM-1). Gane E, Roberts S, Stedman C, Angus P, Ritchie B, Elston R, Ipe D, Morcos P, Baher L, Najera I, Chu T et al J HEPATOL 2010 52 Suppl 1 Abs 749
69. 1106576 National Institutes of Health consensus development conference statement: Management of hepatitis C: 2002 - June 10-12, 2002. NIH HEPATOLOGY 2002 36 5 Suppl 1 3-20
70. 1106577 Review article: Novel therapeutic options for chronic hepatitis C. Cholongitas E, Papatheodoridis GV ALIMENT PHARMACOL THER 2008 27 10 866-884
71. 1106579 Structural biology of hepatitis C virus. Penin F, Dubuisson J, Rey FA, Moradpour D, Pawlotsky JM HEPATOLOGY 2004 39 1 5-19
72. 1106580 Characterization of the genome and structural proteins of hepatitis C virus resolved from infected human liver. Nielsen SU, Bassendine MF, Burt AD, Bevitt DJ, Toms GL J GEN VIROL 2004 85 1497-1507
73. 1106583 Emerging host cell targets for hepatitis C therapy. He YP, Duan W, Tan SL DRUG DISC TODAY 2007 12 5-6 209-217
74. 1106584 Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients. Hinrichsen H, Benhamou Y, Wedemeyer H, Reiser M, Sentjens RE, Calleja JL, Forns X, Erhardt A, Cronlein J, Chaves RL, Yong CL et al GASTROENTEROLOGY 2004 127 5 1347-1355
75. 1106596 High sustained virologic response (SVR) in genotype 1 (G1) null responders to peg-interferon α-2b (P) plus ribavirin (R) when treated with boceprevir (BOC) combination therapy. Kwo PY, Lawitz E, McCone J, Schiff ER, Vierling JM, Pound D, Davis M, Galati JS, Gordon SC, Ravendhran N, Rossaro L et al HEPATOLOGY 2009 50 4 Suppl S Abs 62
76. 1106600 Discovery and preclinical characterization of novel inhibitors of the HCV NS3/4 protease. Seiwert S, Tan H, Rieger R, Lee PA, Andrews SW, Jiang YT, Kennedy AL, Wenglowsky SM, Madduru MR, Bencsik JR, Mi L et al HEPATOLOGY 2004 40 S4 Abs LB14
77. 1106605 Novel potent inhibitors of the HCV NS3/4 protease are well tolerated in multiple animal species and display liver concentrations that predict efficacy. Seiwert S, Tan H, Cheung E, Rieger R, Lee PA, Andrews SW, Jiang YT, Kennedy AL, Wenglowsky SM, Madduru MR, Bencsik JR et al GASTROENTEROLOGY 2005 128 4 A699
78. 1107585 The history of the 'natural history' of hepatitis C (1968-2009). Seeff LB LIVER INT 2009 29 Suppl 1 89-99
79. 1109645 HCV protease inhibitor restores insulin sensitivity in genotype 1 chronic hepatitis C patients. Moucari R, Forestier N, Larrey D, Guyader D, Couzigou P, Benhamou Y, Voitot H, Vidaud M, Seiwert S, Bradford B, Zeuzem S et al J HEPATOL 2010 52 Suppl 1 Abs 283
80. 1109666 The combination of ITMN-191, an orally active inhibitor of the HCV NS3/4A protease inhibitor, and PEG-interferon α-2a results in synergistic antiviral effects in vitro. Tan H, Seiwert S, Blatt LM EUR CYTOKINE NETW 2006 17 Special issue 'Cytokine 2006' Abs 06-29/O
81. 1109672 The safety evaluation of ITMN-191, a novel orally available hepatitis C serine protease inhibitor. Dearlove GE, Marafino Jr BJ, Secrest JT, Smith EA, Seiwert SD, Blatt LM TOXICOLOGIST 2007 96 1 Abs 929
82. 1111039 Investigational drugs for hepatitis C. Flisiak R, Parfieniuk A EXPERT OPIN INVESTIG DRUGS 2010 19 1 63-75
83. 1112251 Genome-wide association of IL28B with response to pegylated interferon-? and ribavirin therapy for chronic hepatitis C. Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, Nakagawa M, Korenaga M, Hino K, Hige S, Ito Y et al NAT GENET 2009 41 10 1105-1109